何氏眼科(301103.SZ)上市首日一度大漲近40%
格隆匯3月22日丨何氏眼科(301103.SZ)今日在深交所創業板上市高開高走,一度大漲近40%至58.87元,市值超70億元。據悉,何氏眼科此次發行價為42.5元,回撥機制啟動後,何氏眼科網上發行最終中籤率僅約0.017568%,申購倍數高達5692.33倍,高於同期大多數創業板註冊制公司。公吿顯示,經初步預計,何氏眼科2021年全年可實現營業收入8.38億元至11.18億元,較2020年增長0.00%至33.34%。何氏眼科還在公吿中透露業務擴張計劃,深耕遼寧市場,佈局以北京為中心的京津冀地區、以上海為中心的長三角地區、以深圳為中心的大灣區以及以成都、重慶為中心的西部地區等地,在各投資區域投資建立眼科專科醫療機構,初步形成遼寧各區域連鎖網絡佈局和全國重點城市戰略佈局。何氏眼科由留學歸國眼科醫學博士、國際眼科理事會(ICO)理事何偉及其團隊創辦,是一家集醫教研於一體,採用三級眼健康醫療服務模式,致力於全生命週期眼健康管理的集團型連鎖醫療機構。此外,瀋陽何氏眼科醫院被評為“國家臨牀重點專科”,同時也是國家衞健委“防盲治盲培訓 基地”、國際眼科理事會眼科專科醫師培訓基地、國家藥物臨牀試驗機構。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.